PTGX Q1 2019 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-85.5% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$15M-939.0% margin

Net Income

-$14M-904.0% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

-33.7%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$132M

Total Liabilities

$31M

Stockholders' Equity

$101M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$11M	-85.5%
Gross Profit	$2M	$11M	-85.5%
Operating Income	-$15M	-$8M	-78.0%
Net Income	-$14M	-$8M	-84.1%

Revenue Segments

License And Collaborative Revenue

$2M100%